Five-year survival and costs of care in metastatic colorectal cancer: Conventional versus monoclonal antibody-based treatment protocols

Expert Review of Anticancer Therapy

Volumn 15, Issue 8, 2015, Pages 963-970

  Kovacevic, Aleksandra ^a   Dragojevic Simic, Viktorija ^a   Tarabar, Dino ^a   Rancic, Nemanja ^a   Jacimovic, Nemanja ^b   Katic, Jelena ^b   Dagovic, Aleksandar ^c   Jakovljevic, Mihajlo ^d  

^a Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c University Clinical Center Kragujevac   (Serbia)

^d University of Kragujevac Medical Faculty   (Serbia)

Author keywords

cancer; colorectal carcinoma; costs; economics; long term; monoclonal antibodies; survival

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOSTATIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE STUDY; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; COST OF ILLNESS; EUROPE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; RETROSPECTIVE STUDY; SERBIA; SURVIVAL RATE; SURVIVAL TIME; AGED; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; METASTASIS; PATHOLOGY; PUBLIC HOSPITAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNIVERSITY HOSPITAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HOSPITALS, MILITARY; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SERBIA; SURVIVAL RATE;

EID: 84937834032     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1059280     Document Type: Article

References (38)

1. Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59(6):366-78
2. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 2005;23(2): 378-91
3. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010;8(1):8-61
4. Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(3):iii1-9
5. Jakovljevic M, Zugic A, Rankovic A, et al. Radiation therapy remains the key cost driver of oncology inpatient treatment. J Med Econ 2015;18(1):29-36
6. Kovacevic AM, Rancic NK, Tarabar DK, et al. Targeted Therapy and Its Availability in Serbia. Hospital Pharmacology 2014; 1(2):93-101
7. Jakovljevic MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health economics and therapeutic pathways 2014; 15(1):27-32
8. Hoyle M, Crathorne L, Peters J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono-or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess 2013;17(14):1-237
9. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14(11): 1077-85
10. Asseburg C, Frank M, Köhne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011;33(4): 482-97
11. Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11(12):1-128
12. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5
13. Faul F, Erdfelder E, Lang AG, et al. G Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91
14. Microsoft. Microsoft Excel. Redmond. Washington: Microsoft, 2007; Computer Software. Microsoft Office Excel RANDBETWEEN function. Available from: http://office.microsoft.com/en-001/ excel-help/randbetween-HP005209230.aspx [Last accessed 3 January 2015]
15. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th edition. Wiley-Blackwell; New York: 2009
16. Radovanovic-A, Dagovic-A, Jakovljevic M. Economics of cancer related medical care: worldwide estimates and available domestic evidence. Arch Oncol 2011;19(3-4):59-63
17. Jakovljevic MB. Health expenditure dynamics in Serbia 1995-2012. Hospital Pharmacol 2014;1(3):180-3
18. Jakovljevic M, Gutzwiller F, Schwenkglenks M, et al. Costs differences among monoclonal antibodies-based firstline oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON 2014; 19(3):1111-20
19. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45(8):1397-406
20. Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16(11):1299-309
21. Van Cutsem E, Köhne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-19
22. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706-12
23. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
24. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009;77:113-19
25. Grothey A, Sugrue MM, Purdie MD, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34
26. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
27. Ebos J, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-9
28. Allegra C, Yothers G, O'Connell M, et al. Phase III trial assessing bevacizhumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29(1):11-16
29. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27(22):3677-83
30. Gray R, Glimelius B, Hills R, et al. Preoperative and postoperative radiotherapy and survival in colorectal cancer. Lancet 2002;359(9311):1069
31. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73(1):198-206
32. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013;14(2):153-9
33. Lange A, Prenzler A, Frank M, et al. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 2014;50(1): 40-9
34. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 2007;29(10):2256-67
35. Gulacsi L. Future challenges for health economics and health technology assessment of biological drugs. Eur J Health Econ 2010;11(3):235-8
36. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23(9):2020-7
37. Dykacz JM. Prospective and retrospective studies. Encyclopedia of Statistics Behavioral Sci 2005;published online 15 October 2005; doi: 10.1002/0470013192.bsa509
38. Jakovljevic M, Jovanovic M, LazicZ, et al. Current efforts and proposals to reduce healthcare costs in Serbia. SJECR 2011; 12(4):161-3